M
Michelle A. Barron
Researcher at University of Colorado Denver
Publications - 64
Citations - 2996
Michelle A. Barron is an academic researcher from University of Colorado Denver. The author has contributed to research in topics: Medicine & Vaccination. The author has an hindex of 18, co-authored 48 publications receiving 1499 citations. Previous affiliations of Michelle A. Barron include University of Colorado Hospital & Anschutz Medical Campus.
Papers
More filters
Journal ArticleDOI
Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022
Jill M. Ferdinands,S. Rao,Brian E. Dixon,Patrick K. Mitchell,Malini B. DeSilva,Stephanie A. Irving,Ned Lewis,Karthik Natarajan,Edward Stenehjem,Shaun J. Grannis,Jungmi Han,Charlene McEvoy,Toan C. Ong,Allison L. Naleway,Sara E. Reese,Peter J. Embi,Kristin Dascomb,Nicola P. Klein,E. Griggs,D. Konatham,Anupam B. Kharbanda,Duck-Hye Yang,William F. Fadel,Nancy Grisel,Kristin Goddard,Palak Patel,I-Chia Liao,Rebecca Birch,Nimish Valvi,Sue Reynolds,Julie Arndorfer,Ousseny Zerbo,M. Dickerson,Kempapura Murthy,Jeremiah Williams,Catherine H Bozio,Lenee Blanton,Jennifer R. Verani,Stephanie J. Schrag,Alexandra F. Dalton,Mehiret Wondimu,Ruth Link-Gelles,Eduardo Azziz-Baumgartner,Michelle A. Barron,Manjusha Gaglani,Mark Thompson,Bruce Fireman +46 more
TL;DR: VE after receipt of a third dose was higher than that after a second dose; however, VE waned with increasing time since vaccination, and VE was generally higher for protection against hospitalizations than against ED/UC visits.
Journal ArticleDOI
Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings.
Mark G. Thompson,Edward Stenehjem,Shaun J. Grannis,Sarah Ball,Allison L. Naleway,Toan C. Ong,Malini B. DeSilva,Karthik Natarajan,Catherine H Bozio,Ned Lewis,Kristin Dascomb,Brian E. Dixon,Rebecca J. Birch,Stephanie A. Irving,Suchitra Rao,Elyse O. Kharbanda,Jungmi Han,Sue Reynolds,Kristin Goddard,Nancy Grisel,William F. Fadel,Matthew E Levy,Jill M. Ferdinands,Bruce Fireman,J.A Arndorfer,Nimish R. Valvi,Elizabeth A Rowley,Palak Patel,Ousseny Zerbo,Eric P. Griggs,Rachael M. Porter,Maria Demarco,Lenee Blanton,Andrea Steffens,Yan Zhuang,Natalie Olson,Michelle A. Barron,Pat Shifflett,Stephanie J. Schrag,Jennifer R. Verani,Alicia M Fry,Manjusha Gaglani,Eduardo Azziz-Baumgartner,Nicola P. Klein +43 more
TL;DR: In this article, the effectiveness of the Ad26.COV2.S vaccine against SARS-CoV-2 infection requiring hospitalization, ICU admission, or an emergency department or urgent care clinic visit was evaluated.
Journal ArticleDOI
Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022
Mark Thompson,Karthik Natarajan,Stephanie A. Irving,Elizabeth Rowley,E. Griggs,Manjusha Gaglani,Nicola P. Klein,Shaun J. Grannis,Malini B. DeSilva,Edward Stenehjem,Sara E. Reese,M. Dickerson,Allison L. Naleway,Jungmi Han,D. Konatham,Charlene McEvoy,S. Rao,Brian E. Dixon,Kristin Dascomb,Ned Lewis,M. Levy,Palak Patel,I-Chia Liao,Anupam B. Kharbanda,Michelle A. Barron,William F. Fadel,Nancy Grisel,Kristin Goddard,Duck-Hye Yang,Mehiret Wondimu,Kempapura Murthy,Nimish Valvi,Julie Arndorfer,Bruce Fireman,M. Dunne,Peter J. Embi,Eduardo Azziz-Baumgartner,Ousseny Zerbo,Catherine H Bozio,Sue Reynolds,Jill M. Ferdinands,Jeremiah Williams,Ruth Link-Gelles,Stephanie J. Schrag,Jennifer R. Verani,Sarah Ball,Toan C. Ong +46 more
TL;DR: The highest estimates of VE against COVID-19-associated ED and UC encounters or hospitalizations during both Delta- and Omicron-predominant periods were among adults who received a third dose of mRNA vaccine, and all unvaccinated persons should get vaccinated as soon as possible.
Journal ArticleDOI
Administration of Spores of Nontoxigenic Clostridium difficile Strain M3 for Prevention of Recurrent C difficile Infection: A Randomized Clinical Trial
Dale N. Gerding,Dale N. Gerding,Thomas L. Meyer,Christine H. Lee,Stuart H. Cohen,Uma K. Murthy,André Poirier,Trevor C. Van Schooneveld,Darrell S. Pardi,Antonio Ramos,Michelle A. Barron,Hongzi Chen,Stephen Villano +12 more
TL;DR: Among patients with CDI who clinically recovered following treatment with metronidazole or vancomycin, oral administration of spores of NTCD-M3 was well tolerated and appeared to be safe and significantly reduced CDI recurrence.
Journal ArticleDOI
Influence of Plasma Viremia on Defects in Number and Immunophenotype of Blood Dendritic Cell Subsets in Human Immunodeficiency Virus 1–Infected Individuals
TL;DR: Highly active antiretroviral therapy suppression of plasma viremia resulted in increases in blood DC numbers and decreases in DC costimulatory molecule expression, which further define the impact of HIV-1 replication on blood DC subsets in vivo.